02889nam 2200697 a 450 991096631390332120240313192123.0978111868218011186821819781299468832129946883797811186822031118682203(CKB)2670000000342126(EBL)1165087(OCoLC)836400729(SSID)ssj0000856518(PQKBManifestationID)12382870(PQKBTitleCode)TC0000856518(PQKBWorkID)10807891(PQKB)10565313(MiAaPQ)EBC1165087(Au-PeEL)EBL1165087(CaPaEBR)ebr10684967(CaONFJC)MIL478133(Perlego)1002802(EXLCZ)99267000000034212620110124d2011 uy 0engur|n|---|||||txtccrNew mechanisms in glucose control /Anthony H. Barnett, Jenny Grice1st ed.Chichester, West Sussex Wiley-Blackwell20111 online resource (74 p.)Description based upon print version of record.9781118682197 111868219X 9781444334616 1444334611 Includes bibliographical references and index.Epidemiology and pathogenesis of type 2 diabetes -- Overview of current diabetes management -- The incretin system -- The incretin mimetics -- Dipeptidyl peptidase-4 inhibitors -- Sodium-glucose cotransporter-2 inhibitors -- Pipeline diabetes therapies -- Bariatric surgery for the treatment of type 2 diabetes -- Organization of diabetes care.New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabeteType 2 diabetesHypoglycemic agentsObesitySurgeryType 2 diabetes.Hypoglycemic agents.ObesitySurgery.616.4/624Barnett A. H(Anthony H.),1951-1621466Grice Jenny1814921MiAaPQMiAaPQMiAaPQBOOK9910966313903321New mechanisms in glucose control4369143UNINA